Skip to main content
. 2019 Jun 18;116(27):13394–13403. doi: 10.1073/pnas.1821401116

Fig. 2.

Fig. 2.

PFKFB3 inhibitor 3PO reduces Sugen 5416/hypoxia (Su/Hx)-induced PH in rats. (A) Real-time PCR analysis of Pfkfb3 mRNA levels in lung homogenates of control rats and Su/Hx-treated rats (n = 6). (B) Western blot analysis and densitometric quantification of Pfkfb3 protein levels in lung homogenates of control rats and Su/Hx-treated rats (n = 5). (C) Relative F-2,6-P2 levels in lung homogenates of control rats and Su/Hx-treated rats (n = 5 for control group, n = 6 for Su/Hx-treated group). (D) Quantification of RVSP, (E) mean pulmonary arterial pressure (mPAP), and (F) RV hypertrophy assessed by the ratio of RV/LV+septum. (G) (Left) Representative images of H&E staining and α-SMA immunostaining of the distal pulmonary arteries of control and treated (Su/Hx + vehicle and Su/Hx + 3PO) rats. (Right) Quantification of the ratio of vessel wall area to total vessel area and α-SMA immunostaining-positive area. (H) Quantitative assessment of nonmuscularized, partially muscularized, and fully muscularized arteries as percentages of total assessed arteries (n = 6–8). All data are expressed as mean ± SEM. Statistical significance was determined by unpaired Student’s t test (A–C) and one-way ANOVA followed by Bonferroni test (D–H). *P < 0.05 was considered significant, **P < 0.01, ***P < 0.001. ns, no significance.